What is CuriRx?
Founded in 2012 and headquartered in Wilmington, Massachusetts, CuriRx operates as a critical infrastructure provider for the global life sciences industry. The company specializes in comprehensive development solutions that span the entire lifecycle of drug manufacturing, including complex pharmaceutics, biopharmaceutics, vaccines, generics, and biosimilars. By offering high-precision analytical and development services, CuriRx enables pharmaceutical entities to navigate the rigorous regulatory landscape while accelerating time-to-market for essential medical therapies. Its role as a technical partner is increasingly vital as the industry shifts toward more complex biologic modalities.
How much funding has CuriRx raised?
CuriRx has raised a total of $478K across 2 funding rounds:
Debt
$150K
Debt
$328K
Debt (2020): $150K with participation from PPP
Debt (2021): $328K led by PPP
Key Investors in CuriRx
PPP
Public-Private Partnership
What's next for CuriRx?
With the recent infusion of capital, CuriRx is well-positioned to scale its operational capacity and expand its suite of development services. The company is expected to leverage this financial backing to enhance its laboratory infrastructure and invest in advanced analytical technologies required for the next generation of biosimilars and vaccine candidates. As the firm transitions through this late-stage growth phase, the focus will likely shift toward increasing market share in the competitive contract development space, potentially through strategic facility upgrades or the acquisition of specialized technical capabilities to meet the rising demand for outsourced biopharmaceutical innovation.
See full CuriRx company page
